dr. J. Blokzijl

No picture available
E-mail:
h.blokzijl umcg.nl

Research

  1. 2020
  2. 2019
  3. 2018
  4. 2017
  5. van Tilborg, M., Lieveld, F. I., Smolders, E. J., van Erpecum, K. J., de Kanter, C. T. M. M., Maan, R., ... HepNed Study Grp (2017). Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. Alimentary Pharmacology & Therapeutics, 46(9), 864-872. https://doi.org/10.1111/apt.14288
  6. 2016
  7. Berden, F. A. C., de Knegt, R. J., Blokzijl, H., Kuiken, S. D., van Erpecum, K. J. L., Willemse, S. B., ... Kievit, W. (2016). Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS ONE, 11(9), [e0161821]. https://doi.org/10.1371/journal.pone.0161821
  8. 2015
  9. Arshad, F., Stoof, S. C. M., Leebeek, F. W. G., Ruitenbeek, K., Adelmeijer, J., Blokzijl, H., ... Lisman, T. (2015). Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis. Liver International, 35(7), 1809-1815. https://doi.org/10.1111/liv.12765
  10. 2014
  11. 2013
  12. 2007

ID: 27976892